Zobrazeno 1 - 10
of 9 522
pro vyhledávání: ''
Autor:
Qian Cheng, Jingwen Tan, Rui Liu, Liqing Kang, Yi Zhang, Erhua Wang, Ying Li, Jian Zhang, Han Xiao, Nan Xu, Minghao Li, Lei Yu, Xin Li
Publikováno v:
Cytotherapy. 24:1026-1034
The infusion of chimeric antigen receptor (CAR) T cells that target specific tumor-associated antigens is a promising strategy that has exhibited encouraging results in clinical trials. However, few studies have focused on the effectiveness and safet
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing
Autor:
Muna, Qayed, Joseph P, McGuirk, G Doug, Myers, Vinod, Parameswaran, Edmund K, Waller, Peter, Holman, Margarida, Rodrigues, Lee F, Clough, Jennifer, Willert
Publikováno v:
Cytotherapy. 24:869-878
Chimeric antigen receptor (CAR) T-cell therapy is an individualized immunotherapy that genetically reprograms a patient's T cells to target and eliminate cancer cells. Tisagenlecleucel is a US Food and Drug Administration-approved CD19-directed CAR T
Autor:
Martin G. Klatt, Tao Dao, Zhiyuan Yang, Jianying Liu, Sung Soo Mun, Megan M. Dacek, Hanzhi Luo, Thomas J. Gardner, Christopher Bourne, Leila Peraro, Zita E. H. Aretz, Tanya Korontsvit, Michael Lau, Michael G. Kharas, Cheng Liu, David A. Scheinberg
Publikováno v:
Blood. 140:861-874
Target identification for chimeric antigen receptor (CAR) T-cell therapies remains challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular proteins presented in the context of cell surface HLA provide a wide pool o
Autor:
Haneen Shalabi, Haiying Qin, Angela Su, Bonnie Yates, Pamela L. Wolters, Seth M. Steinberg, John A. Ligon, Sara Silbert, Kniya DéDé, Mehdi Benzaoui, Sophia Goldberg, Sooraj Achar, Dina Schneider, Shilpa A. Shahani, Lauren Little, Toni Foley, John C. Molina, Sandhya Panch, Crystal L. Mackall, Daniel W. Lee, Christopher D. Chien, Marie Pouzolles, Mark Ahlman, Constance M. Yuan, Hao-Wei Wang, Yanyu Wang, Jon Inglefield, Mary Anne Toledo-Tamula, Staci Martin, Steven L. Highfill, Gregoire Altan-Bonnet, David Stroncek, Terry J. Fry, Naomi Taylor, Nirali N. Shah
Publikováno v:
Blood. 140:451-463
Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B-cell acute
Autor:
Joanna C. Zurko, Huiqing Xu, Katherine Chaney, Dina Schneider, Aniko Szabo, Parameswaran Hari, Bryon D. Johnson, Nirav N. Shah
Publikováno v:
Cytotherapy. 24:767-773
Selective immune pressure contributes to relapse due to target antigen downregulation in patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells. Bispecific lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T cells may prevent progression/
Autor:
Nan Yan, Na Wang, Gaoxiang Wang, Liang Huang, Chunrui Li, Di Wang, Jue Wang, Lifang Huang, Fankai Meng, Jia Wei, Liting Chen, Xia Mao, Jianfeng Zhou, Yicheng Zhang, Yang Cao
Publikováno v:
Cytotherapy. 24:841-849
B cell acute lymphocytic leukemia (B-ALL) patients who have relapsed after hematopoietic stem cell transplantation (HSCT) have a poor prognosis, and there is currently no standard approach available. Chimeric antigen receptor (CAR)-T cells induce hig
Autor:
Mariane Cariati Tirapelle, Ana Luiza Oliveira Lomba, Renata Nacasaki Silvestre, Amanda Mizukami, Dimas Tadeu Covas, Virgínia Picanço-Castro, Kamilla Swiech
Publikováno v:
Cytotherapy. 24:850-860
Lentiviral vectors (LVs) have been used extensively in gene therapy protocols because of their high biosafety profile and capacity to stably express a gene of interest. Production of these vectors for the generation of chimeric antigen receptor (CAR)
Autor:
Djordje Atanackovic, Tim Luetkens, Destiny Omili, Thierry Iraguha, Forat Lutfi, Nancy M. Hardy, Xiaoxuan Fan, Stephanie V. Avila, Kapil K. Saharia, Jennifer S. Husson, Silke V. Niederhaus, Philip Margiotta, Seung T. Lee, Jennie Y. Law, Heather D. Mannuel, Erica Vander Mause, Sherri Bauman, Patricia Lesho, Kim Hankey, John Baddley, Mehmet Kocoglu, Jean A. Yared, Aaron P. Rapoport, Saurabh Dahiya
Publikováno v:
Blood. 140:152-156
Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al d
Autor:
Jordan Gauthier, Nicolas Gazeau, Alexandre V. Hirayama, Joshua A. Hill, Vicky Wu, Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Victor A. Chow, Ajay K. Gopal, Alexandria Hodges Dwinal, Staci Williamson, Jessie Myers, Andy Chen, Sarah Nagle, Brandon Hayes-Lattin, Levanto Schachter, David G. Maloney, Cameron J. Turtle, Mohamed L. Sorror, Richard T. Maziarz
Publikováno v:
Blood
CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T cells are novel therapies showing great promise for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL). Single-arm studies showed significant varia
Autor:
Yuan, Song, Huey Yee, Teo, Yonghao, Liu, Xiaomeng, Zhang, Jinmiao, Chen, Yongliang, Zhang, Haiyan, Liu
Publikováno v:
Journal of Leukocyte Biology. 112:1701-1716
γδT cells recognize and exert cytotoxicity against tumor cells independently of MHC restriction and have antigen presentation and regulatory functions to promote adaptive immune responses. They are considered as potential immune cells for cellular